Associated Genetic Biomarkers
Associated Diseases

Overview

Location [1]
17q22
Protein [2]
DNA repair protein RAD51 homolog 3
Synonyms [1]
R51H3, BROVCA3, FANCO, RAD51L2

RAD 51 paralog C (RAD51C) is a gene that encodes a protein that functions in the homologous recombination and repair of DNA. Missense mutations, silent mutations, and frameshift deletions are observed in cancers such as cancers of the biliary tract, endometrial cancer, and intestinal cancer.

RAD51C is altered in 1.23% of all cancers with breast invasive ductal carcinoma, invasive breast carcinoma, lung adenocarcinoma, bladder urothelial carcinoma, and colon adenocarcinoma having the greatest prevalence of alterations [3].

RAD51C GENIE Cases - Top Diseases

The most common alterations in RAD51C are RAD51C Mutation (0.59%), RAD51C Amplification (0.69%), RAD51C Nonsense (0.07%), RAD51C Fusion (0.02%), and RAD51C Loss (0.02%) [3].

RAD51C GENIE Cases - Top Alterations

Biomarker-Directed Therapies

Significance of RAD51C in Diseases

Prostate Carcinoma +

Malignant Solid Tumor +

Breast Carcinoma +

Ovarian Carcinoma +

Prostate Adenocarcinoma +

Primary Peritoneal Carcinoma +

Fallopian Tube Carcinoma +

Adenocarcinoma Of The Gastroesophageal Junction +

Non-Small Cell Lung Carcinoma +

Pancreatic Adenocarcinoma +

Gastric Carcinoma +

Small Cell Lung Carcinoma +

Urothelial Carcinoma +

Endometrial Carcinoma +

Cervical Carcinoma +

Colorectal Carcinoma +

Gastric Adenocarcinoma +

Non-Hodgkin Lymphoma +

Soft Tissue Sarcoma +

Pancreatic Carcinoma +

Head And Neck Carcinoma +

High Grade Ovarian Serous Adenocarcinoma +

Bladder Urothelial Carcinoma +

Head And Neck Squamous Cell Carcinoma +

Melanoma +

Osteosarcoma +

Gastrointestinal Stromal Tumor +

Squamous Cell Lung Carcinoma +

Malignant Central Nervous System Neoplasm +

Esophageal Adenocarcinoma +

Esophageal Carcinoma +

Clear Cell Renal Cell Carcinoma +

Pancreatic Ductal Adenocarcinoma +

Neuroblastoma +

Invasive Breast Carcinoma +

Bladder Carcinoma +

Malignant Small Intestinal Neoplasm +

Malignant Uterine Neoplasm +

Malignant Mesothelioma +

Diffuse Large B-Cell Lymphoma +

Ampulla Of Vater Carcinoma +

Bile Duct Adenocarcinoma +

Bile Duct Carcinoma +

Cholangiocarcinoma +

Malignant Intestinal Neoplasm +

Colorectal Adenocarcinoma +

Malignant Ovarian Epithelial Tumor +

Lung Carcinoma +

Malignant Esophagogastric Neoplasm +

Glioma +

Biliary Tract Carcinoma +

Rhabdomyosarcoma +

Multiple Myeloma +

Malignant Gastric Neoplasm +

B-Cell Non-Hodgkin Lymphoma +

Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma +

Leiomyosarcoma +

Renal Cell Carcinoma +

Anal Carcinoma +

Bronchogenic Carcinoma +

Esophageal Squamous Cell Carcinoma +

Ewing Sarcoma +

Gallbladder Carcinoma +

High Grade Fallopian Tube Serous Adenocarcinoma +

Histiocytic Sarcoma +

Juvenile Xanthogranuloma +

Langerhans Cell Histiocytosis +

Low Grade Ovarian Serous Adenocarcinoma +

Mantle Cell Lymphoma +

Medulloblastoma +

Ovarian Clear Cell Adenocarcinoma +

Penile Carcinoma +

Primary Peritoneal High Grade Serous Adenocarcinoma +

Vaginal Carcinoma +

Vulvar Carcinoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.